Nobel Prize winner Prof. Dr. Stanley Prusiner joined Priavoid's Supervisory Board
2019
Successful completion of Phase Ib MAD clinical trial with daily dosage up to 320 mg confirming the excellent safety and tolerability profile of PRI-002
Closure of first seed investment by private equity firm Riesner Verwaltungs GmbH
2018
Acquisition of patents from Forschungszentrum Jülich
Successful completion of the first-in-human phase I SAD clinical trial with PRI-002
Start of the Phase I MAD clinical trial for PRI-002 in December 2018
2017
Founding of Priavoid
2013
Basic Research at Forschungszentrum Jülich
Research funding by Forschungszentrum Jülich | Helmholtz Gesellschaft | VW Stiftung | Institut für Physikalische Biologie, Heinrich-Heine-Universität Düsseldorf
